Tag: Anti amyloid

Over 6 million Americans are affected by Alzheimer's disease, a leading cause of cognitive decline. Recent advances have led to FDA approval of new medications for cognitive decline, including Leqembi (lecanemab) and Kisunla (donanemab), marking a new era in treatment by targeting the underlying pathology.

Following its full FDA approval in July 2024, Eli Lilly's Alzheimer's treatment, Kisunla (donanemab), was launched with a list price of $32,000 for a year of treatment. The final cost to patients for this disease-modifying therapy can vary significantly based on treatment duration, insurance coverage, and additional monitoring requirements.

According to the Alzheimer's Association, millions of Americans are affected by Alzheimer's, and recent breakthroughs have led to the approval of several new therapies aimed at the underlying pathology. This article explores *what anti-amyloid drugs are FDA approved*, detailing their mechanism of action, key clinical data, and safety profiles for treating early-stage Alzheimer's disease.